News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US FDA Staff Cautious on Genzyme Corporation’s Newer Myozyme
October 17, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Oct 17 (Reuters) - A mass-produced version of Genzyme Corp's Myozyme showed some similar side effects to a smaller-scale version already on the market, U.S. regulatory staff said in documents released on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
·
3 min read
·
Annalee Armstrong
FDA
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
August 12, 2026
·
1 min read
·
Jef Akst
Manufacturing
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
August 11, 2026
·
1 min read
·
Gabrielle Masson
IN PARTNERSHIP WITH AGC BIOLOGICS
From ex vivo to in vivo: Shaping the next generation of viral vector manufacturing
August 10, 2026
·
8 min read
·
Jennifer C. Smith-Parker
